CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)

被引：6
作者：
Jian, Yuan [1 ]
Zhang, Zhiyao [1 ]
Zhou, Huixing [1 ]
Yang, Guangzhong [1 ]
Geng, Chuanying [1 ]
Wang, Huijuan [1 ]
Gao, Wen [1 ]
Chen, Wenming [1 ]
机构：
[1] Capital Med Univ, Beijing Chaoyang Hosp, Myeloma Res Ctr Beijing, Dept Hematol, Beijing, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词：
multiple myeloma; CD20; t(11; 14); prognosis; survival; GENETIC ABNORMALITIES; THERAPY; CLASSIFICATION; CONSENSUS; SURVIVAL; CRITERIA; BIOLOGY;
D O I：
10.3389/fonc.2022.1061438
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ObjectiveTranslocation (11;14) is one of the most frequent recurrent cytogenetic abnormalities in multiple myeloma (MM), while its clinical prognostic value remains controversial. CD20 expression is uncommon in MM while strongly associated with t(11;14). This study aimed to investigate whether CD20 could provide further prognostic value in MM patients harboring t(11;14). MethodsCD20 expression detected by flow cytometry was retrospectively analyzed in 211 newly diagnosed MM patients with t(11;14). The clinical characteristics and outcomes were analyzed between CD20 positive and negative patients. ResultsCD20 expression was found in 34.6% (73/211) newly diagnosed MM (NDMM) patients with t(11;14), associated with lower serum creatine levels and lower incidence of plasmacytoma. Based on similar treatment regimens, CD20 positive patients had a comparable overall response rate to CD20 negative patients, whereas had a lower CR/sCR (complete response/stringent complete response) rate than the latter (31.4% vs. 46.4%, P =0.045). Nevertheless, CD20 positive patients had a longer tendency of progression-free survival (PFS) (59.0 vs. 29.0 months, P =0.163) and significantly longer overall survival (OS) (99.0 vs. 56.0 months, P=0.003) than CD20 negative patients. Further investigation among CD20 expression proportion showed that strong expression of CD20 (>80% of bone marrow plasma cells) exhibited the longest OS (median not reached, P =0.011). However, the favorable impact of CD20 expression on survival was eliminated with the contaminant presence of cytogenetic abnormalities besides t(11;14). Autologous stem cell transplantation (ASCT) could improve the prognosis of CD20 negative t(11;14) patients. Multivariate analysis confirmed that CD20 expression was an independent favorable indicator for longer OS in t(11;14) MM patients. ConclusionCD20 expression is a favorable prognostic factor in NDMM with t(11;14) and could provide further risk-stratification value in this heterogeneous disease subgroup.
引用
收藏
页数：10
相关论文
共 50 条
[21]   Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients [J].
Geng, Chuanying ;
Yang, Guangzhong ;
Wang, Huijuan ;
Wu, Yin ;
Leng, Yun ;
Zhou, Huixing ;
Zhang, Zhiyao ;
Jian, Yuan ;
Chen, Wenming .
LEUKEMIA & LYMPHOMA, 2021, 62 (04) :883-890
[22]   Reduction rate of monoclonal protein as a useful prognostic factor in standard-risk group of newly diagnosed multiple myeloma [J].
Liu, Min ;
Zhang, Jun-Yu .
WORLD JOURNAL OF CLINICAL CASES, 2023, 11 (24) :5643-5652
[23]   Natural history of t(11;14) multiple myeloma [J].
Lakshman, A. ;
Moustafa, M. Alhaj ;
Rajkumar, S. V. ;
Dispenzieri, A. ;
Gertz, M. A. ;
Buadi, F. K. ;
Lacy, M. Q. ;
Dingli, D. ;
Fonder, A. L. ;
Hayman, S. R. ;
Hobbs, M. A. ;
Gonsalves, W. I. ;
Hwa, Y. L. ;
Kapoor, P. ;
Leung, N. ;
Go, R. S. ;
Lin, Y. ;
Kourelis, T. V. ;
Lust, J. A. ;
Russell, S. J. ;
Zeldenrust, S. R. ;
Kyle, R. A. ;
Kumar, S. K. .
LEUKEMIA, 2018, 32 (01) :131-138
[24]   Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation [J].
Geng, Chuanying ;
Zhou, Huixing ;
Wang, Huijuan ;
Li, Yanchen ;
Leng, Yun ;
Zhang, Zhiyao ;
Jian, Yuan ;
Yang, Guangzhong ;
Chen, Wenming .
BMC CANCER, 2022, 22 (01)
[25]   The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma [J].
Gonsalves, Wilson I. ;
Timm, Michael M. ;
Rajkumar, S. Vincent ;
Morice, William G. ;
Dispenzieri, Angela ;
Buadi, Francis K. ;
Lacy, Martha Q. ;
Dingli, David ;
Leung, Nelson ;
Kapoor, Prashant ;
Kyle, Robert A. ;
Gertz, Morie A. ;
Kumar, Shaji K. .
LEUKEMIA RESEARCH, 2016, 44 :32-39
[26]   Underweight as a risk factor of mortality in patients with newly diagnosed multiple myeloma [J].
Chun-Kuang Tsai ;
Chiu-Mei Yeh ;
Te-Lin Hsu ;
Chia-Ju Li ;
Chian Tin ;
Liang-Tsai Hsiao ;
Yao-Chung Liu ;
Hao-Yuan Wang ;
Po-Shen Ko ;
Po-Min Chen ;
Jin-Hwang Liu ;
Jyh-Pyng Gau ;
Chia-Jen Liu .
Supportive Care in Cancer, 2021, 29 :3991-3999
[27]   Low Barthel index score is a poor prognostic factor for newly diagnosed multiple myeloma patients [J].
Geng, Chuanying ;
Yang, Guangzhong ;
Zhou, Huixing ;
Wang, Huijuan ;
Li, Yanchen ;
Leng, Yun ;
Zhang, Zhiyao ;
Jian, Yuan ;
Chen, Wenming .
CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (06) :2593-2600
[28]   Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting [J].
Bonello, Francesca ;
Cani, Lorenzo ;
D'Agostino, Mattia .
FRONTIERS IN ONCOLOGY, 2022, 12
[29]   Clinical Implications of t(11;14) in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation [J].
Takamatsu, Hiroyuki ;
Yamashita, Takeshi ;
Kurahashi, Shingo ;
Saitoh, Takayuki ;
Kondo, Tadakazu ;
Maeda, Takeshi ;
Nakazawa, Hideyuki ;
Murata, Makoto ;
Narita, Tomoko ;
Kuroda, Junya ;
Hashimoto, Hisako ;
Kawamura, Koji ;
Miyamoto, Toshihiro ;
Honda, Sumihisa ;
Ichinohe, Tatsuo ;
Atsuta, Yoshiko ;
Sunami, Kazutaka .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03) :474-479
[30]   Prognostic value of the nutritional risk index in patients with newly diagnosed multiple myeloma [J].
Limei Zhang ;
Shuzhao Chen ;
Mayan Huang ;
Weida Wang ;
Yang Liang ;
Yun Wang .
Annals of Hematology, 2023, 102 :125-132
12345